↓ Skip to main content

Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

Overview of attention for article published in Journal of Clinical Oncology, February 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (96th percentile)
  • High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

1 blog
93 X users
2 Facebook pages


116 Dimensions

Readers on

346 Mendeley
Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
Published in
Journal of Clinical Oncology, February 2017
DOI 10.1200/jco.2016.71.5292
Pubmed ID

Harold J Burstein, Lada Krilov, Jeanny B Aragon-Ching, Nancy N Baxter, E Gabriela Chiorean, Warren Allen Chow, John Frederick De Groot, Steven Michael Devine, Steven G DuBois, Wafik S El-Deiry, Andrew S Epstein, John Heymach, Joshua Adam Jones, Deborah K Mayer, Rebecca A Miksad, Nathan A Pennell, Michael S Sabel, Richard L Schilsky, Lynn Mara Schuchter, Nadine Tung, Karen Marie Winkfield, Lori J Wirth, Don S Dizon


A MESSAGE FROM ASCO'S PRESIDENT I am pleased to present Clinical Cancer Advances 2017, which highlights the most promising advances in patient-oriented cancer research over the past year. The report gives us an opportunity to reflect on what an exciting time it is for cancer research and how swiftly our understanding of cancer has improved. One year ago, the White House announced the national Cancer Moonshot program to accelerate progress against cancer. This shared vision of progress has reinvigorated the research community, identified new areas of scientific collaboration, and raised our ambitions regarding what may be possible beyond the progress we have already made. When I entered the field 35 years ago, I could not have imagined where we would be today. We can now detect cancer earlier, target treatments more effectively, and manage adverse effects more effectively to enable patients to live better, more fulfilling lives. Today, two of three people with cancer live at least 5 years after diagnosis, up from roughly one of two in the 1970s. This progress has resulted from decades of incremental advances that have collectively expanded our understanding of the molecular underpinnings of cancer. There is no better current example of this than ASCO's 2017 Advance of the Year: Immunotherapy 2.0. Over the last year, there has been a wave of new successes with immunotherapy. Research has proven this approach can be effective against a wide range of hard-to-treat advanced cancers previously considered intractable. Researchers are now working to identify biologic markers that can help increase the effectiveness of treatment and determine who is most likely to benefit from immunotherapy. This knowledge will enable oncologists to make evidence-based decisions so as many patients as possible might benefit from this new type of treatment. Each successive advance builds on the previous hard work of generations of basic, translational, and clinical cancer researchers. Importantly, the advances described in this report would not have been possible without the individuals who volunteered to participate in clinical trials as part of their treatment. To turn the promising vision of a cancer moonshot into meaningful advances, we need sustained, robust federal funding for continued research and innovation. Approximately 30% of the research highlighted in this report was funded, at least in part, through federal dollars appropriated to the National Institutes of Health or the National Cancer Institute. Without this federal investment-unique internationally in scale, duration, and impact for decades-I fear we may lose the forward momentum needed to further the progress we see highlighted in this report. Federal lawmakers can further fuel progress by advancing initiatives that facilitate the use of big data to achieve the common good of high-quality care for all patients. Such programs, like ASCO's CancerLinQ, will rapidly increase the pace of progress and dramatically expand the reach of treatment advances to the millions of patients who are living with cancer today or who will do so in the future. This investment will yield medical, scientific, economic, and societal benefits for years to come. Much work still lies ahead. Many questions remain about how cancer develops and spreads and how best to treat it. As you read through Clinical Cancer Advances 2017, I hope you are as inspired as I am by the gains the clinical cancer research community has made over the past year and by the promise of a new era of advances just over the horizon. Daniel F Hayes, MD, FASCO, FACP ASCO President, 2016 to 2017.

X Demographics

X Demographics

The data shown below were collected from the profiles of 93 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 346 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Canada 2 <1%
United Kingdom 1 <1%
Brazil 1 <1%
China 1 <1%
United States 1 <1%
Unknown 340 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 48 14%
Researcher 46 13%
Student > Ph. D. Student 43 12%
Other 36 10%
Student > Bachelor 33 10%
Other 79 23%
Unknown 61 18%
Readers by discipline Count As %
Medicine and Dentistry 118 34%
Agricultural and Biological Sciences 33 10%
Biochemistry, Genetics and Molecular Biology 31 9%
Pharmacology, Toxicology and Pharmaceutical Science 22 6%
Nursing and Health Professions 16 5%
Other 53 15%
Unknown 73 21%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 63. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 February 2018.
All research outputs
of 26,069,033 outputs
Outputs from Journal of Clinical Oncology
of 22,491 outputs
Outputs of similar age
of 429,402 outputs
Outputs of similar age from Journal of Clinical Oncology
of 308 outputs
Altmetric has tracked 26,069,033 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,491 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.2. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 429,402 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 308 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.